Loading company…
reMYND develops treatments for neurodegenerative diseases and provides research services to pharmaceutical companies.
Founded in 2002 and based in Leuven, Belgium, reMYND is developing oral treatments for Alzheimer’s and Huntington’s disease and operates a contract research division. It raised EUR 12 million in Series B funding in January 2021, including investment from Preventive Cardiology Inc. and BNP Paribas Fortis.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in